Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Is there anything known about how they intend to differentiate this IVIG?

Bank of America Merrill Lynch 2012 Health Care Conference (Transcript) - May 16, 2012

Rick Shea -

....it’s been dubbed the Sialic Switch technology and it's based on a principle of activating an anti-inflammatory pathway by sialylating the Fc-linked glycans of antibodies. And this technology has the potential to increase the potency of these products and in the case of IVIG, which is our first product that would be applying this technology to and has the potential tool to reduce the dose which could provide for a significantly enhanced benefit for patients and also for supply chain.

So this is one area that would be applying this technology because of the platform that can be applied broadly to many different types of antibodies.

http://seekingalpha.com/article/601711-momenta-pharmaceuticals-management-presents-at-bank-of-america-merrill-lynch-2012-health-care-conference-transcript?page=3